This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.
Latest papers
Author Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Nature communications · 2022
Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
The Journal of infectious diseases · 2022
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.
Emerging microbes & infections · 2022
Latest funding
- $50,000
COVID-19 Variant Supplement - Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2
CIHR · 2021 · Co-investigator
- $44,460
COVID-19 Variant Supplement - Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
CIHR · 2021 · Principal investigator
- $141,270
Development of field-deployable and point-of-need diagnostics for SARS-CoV-2 using CRISPR-based technology
CIHR · 2020 · Co-investigator
41 publications.
Author Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T, Cai H, Yao H, Zhou B, Zhang N, van Vlissingen MF, Kuiken T, Han W, GeurtsvanKessel CH, Gong Y, Zhao Y, Shen Q, Qin W, Tian XX, Peng C, Lai Y, Wang Y, Hutter CAJ, Kuo SM, Bao J, Liu C, Wang Y, Richard AS, Raoul H, Lan J, Seeger MA, Cong Y, Rockx B, Wong G, Bi Y, Lavillette D, Li D
Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
Fausther-Bovendo H, Qiu X, Babuadze GG, Azizi H, Pedersen J, Wong G, Kobinger GP
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.
An Y, Li S, Jin X, Han JB, Xu K, Xu S, Han Y, Liu C, Zheng T, Liu M, Yang M, Song TZ, Huang B, Zhao L, Wang W, A R, Cheng Y, Wu C, Huang E, Yang S, Wong G, Bi Y, Ke C, Tan W, Yan J, Zheng YT, Dai L, Gao GF
Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2.
Liu Q, Ding Z, Lan J, Wong G
Three Novel Avastroviruses Identified in Dead Wild Crows.
Zhang C, Yang Y, Hu T, Zhou H, Zhang C, Cao J, Li J, Wang P, Wong G, Wang X, Song H, Gao GF, Shi W, Bi Y
The Application of a Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus.
Cao Z, Jin H, Wong G, Zhang Y, Jiao C, Feng N, Wu F, Xu S, Chi H, Zhao Y, Wang T, Sun W, Gao Y, Yang S, Xia X, Wang H
Crimean-Congo Hemorrhagic Fever Virus in Asia, Africa and Europe.
Shahhosseini N, Wong G, Babuadze G, Camp JV, Ergonul O, Kobinger GP, Chinikar S, Nowotny N
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T, Cai H, Yao H, Zhou B, Zhang N, van Vlissingen MF, Kuiken T, Han W, GeurtsvanKessel CH, Gong Y, Zhao Y, Shen Q, Qin W, Tian XX, Peng C, Lai Y, Wang Y, Hutter CAJ, Kuo SM, Bao J, Liu C, Wang Y, Richard AS, Raoul H, Lan J, Seeger MA, Cong Y, Rockx B, Wong G, Bi Y, Lavillette D, Li D
SARS-CoV-2 spillover transmission due to recombination event.
Shahhosseini N, Wong G, Kobinger GP, Chinikar S
Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern.
Shahhosseini N, Babuadze GG, Wong G, Kobinger GP
COVID-19 Variant Supplement - Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2
Principal investigators: Leclerc, Denis
Keywords: 2019-Ncov; Broad Protection; Coronavirus; Ctl Response; Nanoparticle; Nucleoprotein; Peptide Based Vaccine; Sortase; Vaccine; Vaccine Platform
COVID-19 Variant Supplement - Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
Principal investigators: Kobinger, Gary P; Kozak, Robert A; Wong, Gary C
Keywords: Animal Model; Immunogenicity; Monoclonal Antibodies; Vaccine
Development of field-deployable and point-of-need diagnostics for SARS-CoV-2 using CRISPR-based technology
Principal investigators: Pickering, Bradley
Keywords: Covid-19; Crispr; Diagnostics; High Consequence; Low Cost; Point-Of-Need; Sars-Cov-2; Virology
Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
Principal investigators: Kobinger, Gary P; Kozak, Robert A; Wong, Gary C
Keywords: Animal Model; Immunogenicity; Monoclonal Antibodies; Vaccine
Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2
Principal investigators: Leclerc, Denis
Keywords: 2019-Ncov; Broad Protection; Coronavirus; Ctl Response; Nanoparticle; Nucleoprotein; Peptide Based Vaccine; Sortase; Vaccine; Vaccine Platform
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine
- Health Research Methods, Evidence, and Impact
- Microbiologie et d'infectiologie
- General Internal Medicine
- Vaccine and Infectious Disease Organization
- Pediatrics
- Other
Co-authors at Université Laval, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Darwyn Kobasa
Faculty
2 shared papers, latest 2021
Holger Schunemann
Health Research Methods, Evidence, and Impact
1 shared papers, latest 2019
Derek Chu
Medicine
1 shared papers, latest 2019
Susan Waserman
Medicine
1 shared papers, latest 2019
Teresa To
Pediatrics
1 shared papers, latest 2019
Steven Theriault
Faculty
1 shared papers, latest 2021
Anand Kumar
General Internal Medicine
1 shared papers, latest 2021
Jan Brozek
Health Research Methods, Evidence, and Impact
1 shared papers, latest 2019
Darryl Falzarano
Vaccine and Infectious Disease Organization
1 shared papers, latest 2021
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.